The Cold Storage Glut Is Real. Pharma-Grade Capacity Is Still Tight.
Why Life Sciences Manufacturers Should Not Read the Oversupply Headlines as Their Story
The cold storage industry is working through an oversupply. After a speculative construction boom that added roughly 14.5% capacity between 2021 and 2025, the sector is now absorbing an estimated 10% oversupply, and capacity growth is decelerating sharply as developers and lenders pull back from new projects. Read on its own, that data suggests temperature-controlled storage is easy to find and getting cheaper.
For a life sciences manufacturer that needs FDA-registered, cGMP-compliant storage for raw materials, work-in-process, or finished product, that reading is misleading. The cold storage oversupply is concentrated in general-purpose refrigerated space, much of it built for food and bulk perishables. Pharmaceutical-grade storage is a different market with different economics, and within the broader cold storage sector, pharmaceutical cold chain is consistently identified as the fastest-growing demand segment, not an oversupplied one.
A manufacturer who reads “cold storage is oversupplied” and assumes validated pharmaceutical capacity will be easy to secure is reading the wrong segment of the market. General refrigerated space and cGMP-compliant pharmaceutical storage are not interchangeable, and the forces loosening one are not loosening the other.
Two Markets That Get Reported as One
Cold storage tends to be discussed as a single category in industry coverage and real estate reporting. In practice, it splits into segments with very different supply and demand dynamics, and the gap between them matters enormously for a life sciences manufacturer trying to plan capacity.
The oversupply that dominates recent headlines is concentrated in general-purpose cold storage: the large refrigerated and frozen warehouses that serve food processing, grocery distribution, and bulk perishables. That segment saw heavy speculative construction during the pandemic years, and it is now working through the resulting excess. Frozen storage alone accounts for roughly half of total cold storage demand, and much of the new speculative capacity was built for exactly that kind of high-volume, food-oriented use.
Pharmaceutical-grade storage is a fundamentally different product. It requires FDA registration, cGMP-compliant quality systems, validated temperature zones, continuous monitoring, audit-ready documentation, and often security certifications like CTPAT. A food-grade frozen warehouse with empty pallet positions does not meet those requirements, and it cannot be casually converted to meet them. The oversupply in one segment does very little to ease capacity in the other.
| Consideration | General Cold Storage | Pharma-Grade cGMP Storage |
|---|---|---|
| What the headlines describe | General cold storage (food, beverage, bulk perishables) | cGMP-compliant pharmaceutical storage |
| Current supply picture | Working through an estimated 10% oversupply after a 2021 to 2025 building boom | Fastest-growing demand segment; validated capacity remains tight in many markets |
| Capacity growth in 2026 | Decelerating sharply as speculative building pulls back | Demand rising with biologics, GLP-1, and specialty medicine pipelines |
| Regulatory requirements | Temperature control and food safety standards | FDA registration, cGMP, validated temperature zones, audit-ready documentation |
| Substitutability | A pallet position is largely a pallet position | A food-grade cooler is not a substitute for validated pharmaceutical storage |
Why Pharmaceutical Storage Demand Keeps Rising
While general cold storage absorbs its oversupply, the demand drivers for pharmaceutical-grade storage continue to strengthen. Several forces are converging:
Biologics and Specialty Medicine Pipeline
The pharmaceutical pipeline has shifted decisively toward biologics, cell and gene therapies, and other specialty medicines that require refrigerated or frozen storage throughout the supply chain. The gene, cell, and RNA therapy pipeline reached thousands of therapies in development as of 2025, and specialty medicines are projected to account for a growing majority of new drug launches. Nearly all of these products require validated cold chain storage that general refrigerated space cannot provide.
The GLP-1 Surge
The explosive growth of GLP-1 medications for diabetes and weight management has created substantial new demand for pharmaceutical-grade refrigerated storage and handling. These are temperature-sensitive biologics produced and distributed at enormous scale, and they require cold chain infrastructure that meets pharmaceutical, not food-grade, standards.
Reshoring and Domestic Manufacturing
The wave of U.S. pharmaceutical manufacturing investment now underway is generating new domestic demand for validated raw-material and finished-product storage. As more pharmaceutical production happens on U.S. soil, the need for compliant warehousing to stage imported inputs and hold finished product grows alongside it.
Supply Resilience and Safety Stock
The supply chain disruptions of recent years have made pharmaceutical companies more willing to hold safety stock of critical products and inputs. That strategic inventory requires validated storage capacity, adding to demand that is structural rather than temporary.
The Risk of Misreading the Market
The practical danger for a life sciences manufacturer is straightforward. A company that reads the cold storage oversupply headlines and concludes that validated pharmaceutical storage will be readily available, and cheap, when it needs it may delay a capacity decision that should be made proactively. Then, when a production ramp, a commercial launch, or an inventory surge creates an urgent need, the specific validated, FDA-registered, cGMP-compliant space required may not be available in the right location on the timeline the business needs.
Validated pharmaceutical storage cannot be stood up overnight. Whether a manufacturer builds it internally or secures it through a qualified partner, the process of qualifying space, validating temperature zones, and establishing compliant quality systems takes time. A general-purpose cold storage glut provides no cushion against that reality, because the empty space in the glut is the wrong kind of space.
The headline that matters for a life sciences manufacturer is not “cold storage is oversupplied.” It is “pharmaceutical-grade cold chain is the fastest-growing demand segment.” Those two facts are both true at the same time, and only the second one describes the market a manufacturer actually operates in.
What Life Sciences Manufacturers Should Do
Given the gap between the general cold storage picture and the pharmaceutical-grade reality, a few practical priorities follow for manufacturers planning their storage strategy:
- Plan capacity against pharmaceutical-grade supply, not general cold storage headlines. The oversupply in food-grade space is irrelevant to your validated storage needs
- Decide proactively, not reactively. Secure validated storage capacity before a production ramp or launch forces an urgent decision, when options are fewer and timelines are tighter
- Evaluate qualified partners early. A relationship with an FDA-registered, cGMP-compliant storage partner can provide capacity faster than building internally, but the qualification process still takes time to do properly
- Weigh location alongside capacity. Validated space in the wrong region adds transit time and freight cost. Proximity to your manufacturing and distribution footprint matters
- Confirm the specifics, not just the label. “Temperature-controlled” is not the same as validated cGMP storage. Confirm FDA registration, validated zones, monitoring, and documentation
How Euro-American Worldwide Logistics Fits
Euro-American Worldwide Logistics operates a 45,000 square foot FDA-registered, cGMP-compliant facility in Worcester, Massachusetts, with 25,000 square feet of dual temperature-controlled refrigeration supporting validated 2 to 8 degrees C and 15 to 25 degrees C storage. This is pharmaceutical-grade storage built and maintained for FDA-regulated products, not general cold storage repurposed for pharmaceutical use.
For life sciences manufacturers in the Northeast evaluating storage capacity, whether for raw material staging, safety stock, overflow, or finished-product distribution, we provide validated storage with continuous monitoring, ISO-9001 certified quality systems, CTPAT-certified security, and the integrated customs brokerage and freight forwarding that support internationally sourced materials. And we are positioned centrally in the Massachusetts life sciences corridor, close to the manufacturers and research institutions we serve.
If you are planning your pharmaceutical storage strategy and want to talk through validated capacity that fits your requirements and timeline, contact our team today.
Sources include Westside Construction Group analysis of the 2026 cold storage construction cycle; Future Market Insights and DataM Intelligence cold chain market data; GCCA Cold Facts 2026 outlook; and American Society of Gene & Cell Therapy pipeline data. Market figures reflect the cited sources and span differing methodologies and time horizons.
